Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
| Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
| Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
| Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn |
Last Updated : May 15, 2024